Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

Failure to predict response to immunotherapy (IO) limited its benefit in the treatment of head and neck squamous cell cancer (HNSCC) to 20% of patients or less. Biomarkers including tumor mutational burden (TMB) and programmed death ligand-1 (PD-L1) were evaluated as predictors of response to IO, bu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2021-11, Vol.13 (22), p.5733
Hauptverfasser:	Burcher, Kimberly M., Lantz, Jeffrey W., Gavrila, Elena, Abreu, Arianne, Burcher, Jack T., Faucheux, Andrew T., Xie, Amy, Jackson, Clayton, Song, Alexander H., Hughes, Ryan T., Lycan, Thomas, Bunch, Paul M., Furdui, Cristina M., Topaloglu, Umit, D’Agostino, Ralph B., Zhang, Wei, Porosnicu, Mercedes
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Biomarkers Chemotherapy Clinical trials Demography FDA approval Head & neck cancer Head and neck carcinoma Immune checkpoint inhibitors Immunotherapy Medical prognosis Metastasis Mutation Patients PD-1 protein PD-L1 protein Precision medicine Risk factors Squamous cell carcinoma Standardization Statistical analysis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!